Cargando…
mTOR Inhibitors as Radiosensitizers in Neuroendocrine Neoplasms
Peptide receptor radioligand therapy (PRRT) has evolved as an important second-line treatment option in the management of inoperable and metastatic neuroendocrine neoplasms (NEN). Though high radiation doses can be delivered to the tumors, complete remission is still rare. Radiosensitization prior t...
Autores principales: | Exner, Samantha, Arrey, Gerard, Prasad, Vikas, Grötzinger, Carsten |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897674/ https://www.ncbi.nlm.nih.gov/pubmed/33628728 http://dx.doi.org/10.3389/fonc.2020.578380 |
Ejemplares similares
-
Octreotide Does Not Inhibit Proliferation in Five Neuroendocrine Tumor Cell Lines
por: Exner, Samantha, et al.
Publicado: (2018) -
PI3K/mTOR Dual Inhibitor PF-04691502 Is a Schedule-Dependent Radiosensitizer for Gastroenteropancreatic Neuroendocrine Tumors
por: Chow, Zeta, et al.
Publicado: (2021) -
Virtual Screening and Optimization of Novel mTOR Inhibitors for Radiosensitization of Hepatocellular Carcinoma
por: Feng, Ying-Qi, et al.
Publicado: (2020) -
The Role of mTOR Inhibitors in Hematologic Disease: From Bench to Bedside
por: Feng, Yimei, et al.
Publicado: (2021) -
The Paradox of Akt-mTOR Interactions
por: Vadlakonda, Lakshmipathi, et al.
Publicado: (2013)